In early January 2026, Erasca reported early clinical data showing confirmed and unconfirmed partial responses plus favorable ...

Erasca extended gains to a second day on Wednesday to hit a new three-year high, as investors continued to load up on shares ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...